Log in
(Ad)
Located just 25 miles from Cleveland... is a supergreenhouse unlike anything we've ever seen. Listed at over 1.4 million sq ft, (the size of 9 full-sized Costco warehouses), this marijuana grow house is capable of producing over 341,000 pounds of weed/year! And very soon it will come online and could turn a tiny 60-cent pot company into the dominator in the white-hot weed market.

NYSEARCA:XBI - SPDR S&P Biotech ETF Stock Price, Forecast & News

$93.26
-1.23 (-1.30 %)
(As of 01/24/2020 03:03 AM ET)
Add
Today's Range
$92.35
Now: $93.26▼
$94.22
50-Day Range
$92.92
MA: $95.43▼
$98.72
52-Week Range
$72.97
Now: $93.26▼
$98.79
Volume6.13 million shs
Average Volume5.83 million shs
Market Capitalization$4.45 billion
P/E RatioN/A
Dividend Yield0.02%
BetaN/A
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.

Basic Details

Issuer SSgA
Fund NameSPDR S&P Biotech ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:XBI
Inception Date1/31/2006
Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio
Webhttp://www.spdrs.com/
Phone+1-866-7872257

Fund Focus

Asset ClassEquity
BenchmarkS&P Biotech Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$4.48 billion
Average Daily Volume$4.58 million
Discount/Premium0.04%

ETF Expenses

Management Fee0.35%
Other Expenses0.00%
Total Expenses0.35%
Fee Waiver0.00%
Net Expenses0.35%

Administrator, Advisor and Custodian

AdministratorSSGA Funds Management, Inc.
AdvisorSSgA Funds Management, Inc.
CustodianState Street Bank and Trust Company
DistributorState Street Global Advisors Funds Distributors, LLC
Transfer AgentState Street Bank and Trust Company
Trustee
Lead Market MakerVirtu Financial

Receive XBI News and Ratings via Email

Sign-up to receive the latest news and ratings for XBI and its competitors with MarketBeat's FREE daily newsletter.

AMEX:XBI Rates by TradingView

Geographic Exposure of SPDR S&P Biotech ETF (NYSEARCA:XBI)
Currency Exposure of SPDR S&P Biotech ETF (NYSEARCA:XBI)
Sector Exposure of SPDR S&P Biotech ETF (NYSEARCA:XBI)
Industry Exposure of SPDR S&P Biotech ETF (NYSEARCA:XBI)

(Ad)

Located just 25 miles from Cleveland... is a supergreenhouse unlike anything we've ever seen. Listed at over 1.4 million sq ft, (the size of 9 full-sized Costco warehouses), this marijuana grow house is capable of producing over 341,000 pounds of weed/year! And very soon it will come online and could turn a tiny 60-cent pot company into the dominator in the white-hot weed market.

SPDR S&P Biotech ETF (NYSEARCA:XBI) Frequently Asked Questions

What is SPDR S&P Biotech ETF's stock symbol?

SPDR S&P Biotech ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "XBI."

How often does SPDR S&P Biotech ETF pay dividends? What is the dividend yield for SPDR S&P Biotech ETF?

SPDR S&P Biotech ETF announced a quarterly dividend on Friday, December 20th. Stockholders of record on Monday, December 23rd will be given a dividend of $0.0009 per share on Thursday, December 26th. This represents a $0.00 dividend on an annualized basis and a dividend yield of 0.00%. The ex-dividend date is Friday, December 20th. View SPDR S&P Biotech ETF's Dividend History.

Has SPDR S&P Biotech ETF been receiving favorable news coverage?

Headlines about XBI stock have trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. SPDR S&P Biotech ETF earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned press coverage about the exchange traded fund a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for SPDR S&P Biotech ETF.

What other stocks do shareholders of SPDR S&P Biotech ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Biotech ETF investors own include NVIDIA (NVDA), iShares Nasdaq Biotechnology ETF (IBB), Netflix (NFLX), Intel (INTC), Walt Disney (DIS), Alibaba Group (BABA), Micron Technology (MU), Financial Select Sector SPDR Fund (XLF), Cisco Systems (CSCO) and AT&T (T).

Who are SPDR S&P Biotech ETF's key executives?

SPDR S&P Biotech ETF's management team includes the folowing people:
  • James E. Ross, President, Trustee (Age 52)
  • Peter A. Ambrosini, Chief Compliance Officer (Age 69)
  • Michael P. Riley, Vice President (Age 44)
  • Gary L. French, Treasurer (Age 64)
  • John W. Clark, Assistant Treasurer (Age 46)
  • Matthew W. Flaherty, Assistant Treasurer (Age 42)
  • Chad C. Hallett, Assistant Treasurer of Street tracks series trust (Age 47)
  • Mary Moran Zeven, Secretary (Age 52)
  • Scott M. Zoltowski, Assistant Secretary (Age 44)
  • Dave Kelly, Independent Trustee

Who are SPDR S&P Biotech ETF's major shareholders?

SPDR S&P Biotech ETF's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Cumberland Advisors Inc. (0.50%), Howard Capital Management (0.42%), Weatherly Asset Management L. P. (0.34%), Tocqueville Asset Management L.P. (0.36%), Janney Montgomery Scott LLC (0.28%) and BTR Capital Management Inc. (0.23%).

Which major investors are selling SPDR S&P Biotech ETF stock?

XBI stock was sold by a variety of institutional investors in the last quarter, including Reilly Financial Advisors LLC, OLD Second National Bank of Aurora, Cumberland Advisors Inc., Winfield Associates Inc., Cribstone Capital Management LLC, Alpine Global Management LLC, IFP Advisors Inc and Courier Capital LLC.

Which major investors are buying SPDR S&P Biotech ETF stock?

XBI stock was bought by a variety of institutional investors in the last quarter, including Segment Wealth Management LLC, Howard Capital Management, Brick & Kyle Associates, Bridger Capital Management LLC, Tocqueville Asset Management L.P., Weatherly Asset Management L. P., J.W. Cole Advisors Inc. and Roble Belko & Company Inc.

How do I buy shares of SPDR S&P Biotech ETF?

Shares of XBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is SPDR S&P Biotech ETF's stock price today?

One share of XBI stock can currently be purchased for approximately $93.26.

How big of a company is SPDR S&P Biotech ETF?

SPDR S&P Biotech ETF has a market capitalization of $4.45 billion. View Additional Information About SPDR S&P Biotech ETF.

What is SPDR S&P Biotech ETF's official website?

The official website for SPDR S&P Biotech ETF is http://www.spdrs.com/.

How can I contact SPDR S&P Biotech ETF?

SPDR S&P Biotech ETF's mailing address is One Lincoln Street, Boston, 02111, United States. The exchange traded fund can be reached via phone at +1-866-7872257.


MarketBeat Community Rating for SPDR S&P Biotech ETF (NYSEARCA XBI)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  106 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  232
MarketBeat's community ratings are surveys of what our community members think about SPDR S&P Biotech ETF and other stocks. Vote "Outperform" if you believe XBI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Featured Article: Asset Allocation, Balancing Your Investments
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel